CA2709027A1 - Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) - Google Patents

Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) Download PDF

Info

Publication number
CA2709027A1
CA2709027A1 CA2709027A CA2709027A CA2709027A1 CA 2709027 A1 CA2709027 A1 CA 2709027A1 CA 2709027 A CA2709027 A CA 2709027A CA 2709027 A CA2709027 A CA 2709027A CA 2709027 A1 CA2709027 A1 CA 2709027A1
Authority
CA
Canada
Prior art keywords
day
melanoma
dosage
ctla4
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2709027A
Other languages
English (en)
French (fr)
Inventor
Israel Rios
Cynthia W. Tuthill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2709027A1 publication Critical patent/CA2709027A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2709027A 2007-12-12 2008-12-08 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) Abandoned CA2709027A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310107P 2007-12-12 2007-12-12
US61/013,101 2007-12-12
PCT/US2008/013480 WO2009075813A1 (en) 2007-12-12 2008-12-08 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)

Publications (1)

Publication Number Publication Date
CA2709027A1 true CA2709027A1 (en) 2009-06-18

Family

ID=40755783

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709027A Abandoned CA2709027A1 (en) 2007-12-12 2008-12-08 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)

Country Status (8)

Country Link
US (1) US20100330093A1 (https=)
EP (1) EP2240195A4 (https=)
JP (1) JP2011506436A (https=)
CN (1) CN101896190A (https=)
AR (1) AR069682A1 (https=)
AU (1) AU2008335840A1 (https=)
CA (1) CA2709027A1 (https=)
WO (1) WO2009075813A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
WO2013177102A2 (en) * 2012-05-21 2013-11-28 Felder Mitchell S Treatment of cancer by manipulating the immune system
EP3943101A1 (en) * 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
WO2016133059A1 (ja) * 2015-02-16 2016-08-25 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
IT201900016310A1 (it) * 2019-09-13 2021-03-13 Luigina Romani Timosina alfa 1 per l’uso nella prevenzione e nel trattamento degli effetti avversi immunitari correlati agli inibitori di checkpoint immunitari.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy

Also Published As

Publication number Publication date
US20100330093A1 (en) 2010-12-30
AR069682A1 (es) 2010-02-10
WO2009075813A1 (en) 2009-06-18
EP2240195A1 (en) 2010-10-20
EP2240195A4 (en) 2011-12-21
JP2011506436A (ja) 2011-03-03
CN101896190A (zh) 2010-11-24
AU2008335840A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
US20100330093A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
ES2824120T3 (es) Procedimientos de tratamiento del cáncer usando inhibidores de b-raf e inhibidores de los puntos de control inmunitario
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
ZA200309060B (en) Combination therapy using anit-angiogenic agents and TNFalpha.
US20050112061A1 (en) Use of a VEGF antagonist in combination with radiation therapy
US10881708B2 (en) Ang (1-7) derivative oligopeptides for the treatment of pain
US20050196340A1 (en) Use of a VEGF antagonist in combination with radiation therapy
CA2708168A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
CN111836647A (zh) Cd47阻断疗法和cd38抗体的组合
JP6782932B2 (ja) Ｎｐｒ−ａアゴニストの新規用途
EP1450850B1 (en) Method of administering a thymosin alpha 1 peptide
AU2019235627B2 (en) Improvements in CD47 blockade therapy by EGFR antibody
RU2639445C2 (ru) Лекарственное средство, содержащее рекомбинантные лектины омелы, для лечения злокачественной меланомы
US11497793B2 (en) Compositions and methods for treating glioblastoma
US10028906B2 (en) Method and kit for treating a solid tumor and associated desmoplasia
US20100267637A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
US20260098097A1 (en) Immunotoxin-based targeted therapy for cancer
WO2018088933A1 (en) Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
CN117281902A (zh) 一种药物组合物在制备治疗黑色素瘤产品中的应用
WO2011054894A1 (en) Composition for treating insulin resistance

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20141209